Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for AX-0811 (RNA Editing Oligonucleotide) in Cholestatic Diseases. The expected timing is based on the latest available company guidance and may change.
05/12/26:- AX-0811 CTA filing expected Mid-2026, with initial HV data by year-end 2026. 06/25/26:- Preclinical cholestasis model supports AX-0811; CTA Mid-2026, initial HV data Year-End 2026. 08/13/26:- AX-0811 CTA was submitted in July. Initial Ph1 healthy-volunteer data is expected by Year-End 2026, pending authorization.
Verification
Confirm timing and program details against the company announcement or filing.